PL1603584T3 - Aplidyna do leczenia szpiczaka mnogiego - Google Patents

Aplidyna do leczenia szpiczaka mnogiego

Info

Publication number: PL1603584T3
Authority: PL; Poland
Prior art keywords: aplidine; multiple myeloma; myeloma treatment; treatment; medicament
Prior art date: 2003-03-12

Application number

PL04720081T

Other languages

English (en)

Inventor

Joseph R Bertino

Daniel Medina

Glynn Thomas Faircloth

Constantine S Mitsiades

Kenneth Anderson

Nicholas Mitsiades

Original Assignee

Dana Farber Cancer Inst Inc

Pharma Mar Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-12

Filing date

2004-03-12

Publication date

2009-02-27

2004-03-12 Application filed by Dana Farber Cancer Inst Inc, Pharma Mar Sa filed Critical Dana Farber Cancer Inst Inc

2009-02-27 Publication of PL1603584T3 publication Critical patent/PL1603584T3/pl

Links

UUSZLLQJYRSZIS-LXNNNBEUSA-N plitidepsin Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)C(C)=O UUSZLLQJYRSZIS-LXNNNBEUSA-N 0.000 title abstract 3
208000034578 Multiple myelomas Diseases 0.000 title abstract 2
206010035226 Plasma cell myeloma Diseases 0.000 title abstract 2
229950008499 plitidepsin Drugs 0.000 title abstract 2
108010049948 plitidepsin Proteins 0.000 title abstract 2
239000003814 drug Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
Steroid Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

PL04720081T 2003-03-12 2004-03-12 Aplidyna do leczenia szpiczaka mnogiego PL1603584T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US45412503P	2003-03-12	2003-03-12
US52029303P	2003-11-14	2003-11-14
EP04720081A EP1603584B1 (en)	2003-03-12	2004-03-12	Aplidine for multiple myeloma treatment
PCT/GB2004/001062 WO2004080477A1 (en)	2003-03-12	2004-03-12	Aplidine for multiple myeloma treatment

Publications (1)

Publication Number	Publication Date
PL1603584T3 true PL1603584T3 (pl)	2009-02-27

Family

ID=32994545

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL04720081T PL1603584T3 (pl)	2003-03-12	2004-03-12	Aplidyna do leczenia szpiczaka mnogiego

Country Status (20)

Country	Link
US (1)	US7381703B2 (pl)
EP (1)	EP1603584B1 (pl)
JP (1)	JP4584245B2 (pl)
KR (1)	KR101160320B1 (pl)
AT (1)	ATE406171T1 (pl)
AU (1)	AU2004218883B2 (pl)
CA (1)	CA2519789C (pl)
CY (1)	CY1108599T1 (pl)
DE (1)	DE602004016126D1 (pl)
DK (1)	DK1603584T3 (pl)
ES (1)	ES2312979T3 (pl)
IL (1)	IL170136A (pl)
MX (1)	MXPA05009742A (pl)
NO (1)	NO334264B1 (pl)
NZ (1)	NZ541611A (pl)
PL (1)	PL1603584T3 (pl)
PT (1)	PT1603584E (pl)
RU (1)	RU2335294C2 (pl)
SI (1)	SI1603584T1 (pl)
WO (1)	WO2004080477A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL149488A0 (en) *	1999-11-15	2002-11-10	Pharma Mar Sa	Pharmaceutical compositions containing aplidine
KR20060002778A (ko)	2003-03-12	2006-01-09	파르마 마르, 에스.에이.	개선된 항종양 치료
US20090226465A1 (en) *	2005-10-31	2009-09-10	Jackson David Y	Macrocyclic depsipeptide antibody-drug conjugates and methods
HUE028055T2 (en) *	2006-02-28	2016-11-28	Pharma Mar Sa	Improved treatment of myeloma multiplex
WO2008080956A1 (en) *	2006-12-29	2008-07-10	Pharma Mar, S.A.	Prognostic molecular markers for the cancer therapy with aplidine
WO2009002553A1 (en) *	2007-06-25	2008-12-31	Prolexys Pharmaceuticals, Inc.	Methods of treating multiple myeloma and resistant cancers
AU2008313627A1 (en) *	2007-10-19	2009-04-23	Pharma Mar, S.A.	Improved antitumoral treatments
CN101965191A (zh) *	2008-03-07	2011-02-02	法马马有限公司	改善的抗癌治疗
AU2009248039B2 (en) *	2008-05-16	2014-07-31	Pharma Mar, S.A.	Multiple myeloma treatments
LT3615544T (lt)	2017-04-27	2023-05-10	Pharma Mar S.A.	Priešnavikiniai junginiai

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4950649A (en) *	1980-09-12	1990-08-21	University Of Illinois	Didemnins and nordidemnins
US4493796A (en) *	1980-09-12	1985-01-15	Board Of Trustees, Univ. Of Ill.	Didemnins A, B, C, and derivatives thereof, as antiviral agents
DE3161556D1 (en)	1980-09-12	1984-01-05	Univ Illinois	Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
IT1153974B (it) *	1982-09-23	1987-01-21	Erba Farmitalia	Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4948791A (en)	1989-04-10	1990-08-14	The Board Of Trustees Of The University Of Illinois	Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
GB8922026D0 (en) *	1989-09-29	1989-11-15	Pharma Mar Sa	Novel anti-viral and cytotoxic agent
DE4120327A1 (de)	1991-06-20	1992-12-24	Basf Ag	Neue peptide, ihre herstellung und verwendung
US5462726A (en) *	1993-12-17	1995-10-31	Bristol-Myers Squibb Company	Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
DE69431071T2 (de) *	1993-12-29	2003-03-20	Matrix Pharma	Zusammensetzung für lokale freigabe von zytostatika
PT706799E (pt) *	1994-09-16	2002-05-31	Merck Patent Gmbh	Imunoconjugados ii
US5861439A (en) *	1994-11-14	1999-01-19	Alza Corporation	Method for enhanced electrotransport agent delivery
ES2102322B1 (es)	1995-07-13	1998-03-01	Pharma Mar Sa	Procedimiento de preparacion de didemnina a.
EP0914116B1 (en) *	1996-05-22	2000-10-11	Protarga Inc.	Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
US6156724A (en) *	1996-06-07	2000-12-05	Rinehart; Kenneth L.	Uses of didemnins as immunomodulating agents
AU3353897A (en)	1996-07-03	1998-02-02	Mckechnie Uk Limited	Container
JP2001503746A (ja)	1996-10-24	2001-03-21	ザ・ボード・オブ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・イリノイ	ジデムニン類似体の半合成法
JP2001504814A (ja)	1996-10-24	2001-04-10	ザ・ボード・オブ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・イリノイ	ジデムニンＡのアミノＨｉｐ類似体の全合成
US6034058A (en) *	1997-04-15	2000-03-07	Rinehart; Kenneth L.	Semi-synthetic alanyl dilemnin analogs
WO1998050048A1 (en) *	1997-05-07	1998-11-12	Pharma Mar, S.A.	Aplidine as an l-type calcium channel enhancer
GB9803448D0 (en)	1998-02-18	1998-04-15	Pharma Mar Sa	Pharmaceutical formulation
DE69923322T2 (de)	1998-07-30	2005-12-22	Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.	Verwendung von propionyl-l-carnitin und acetyl-l-carnitin zur herstellung von arzneimittel mit antikrebs wirkung
US20010021380A1 (en) *	1999-04-19	2001-09-13	Pluenneke John D.	Soluble tumor necrosis factor receptor treatment of medical disorders
HK1046846A1 (zh)	1999-05-25	2003-01-30	Point Therapeutics, Inc.	包含boroproline的抗肿瘤复合物
US6890904B1 (en) *	1999-05-25	2005-05-10	Point Therapeutics, Inc.	Anti-tumor agents
IL149488A0 (en) *	1999-11-15	2002-11-10	Pharma Mar Sa	Pharmaceutical compositions containing aplidine
ES2272462T3 (es)	2000-04-07	2007-05-01	The Trustees Of The University Of Pennsylvania	Analogos de tamadarina y didemnina y procedimiento de fabricacion y uso.
US6509315B1 (en) *	2000-04-07	2003-01-21	The Trustees Of The University Of Pennsylvania	Didemnin analogs and fragments and methods of making and using them
UA76718C2 (uk)	2000-06-30	2006-09-15	Фарма Мар, С.А.	Протипухлинні похідні аплідину
AU1305302A (en) *	2000-10-05	2002-04-15	Immunex Corp	Nectin polypeptides, polynucleotides, methods of making and use thereof
WO2002030441A2 (en) *	2000-10-12	2002-04-18	Pharma Mar, S.A.	Treatment of cancers by aplidine in conjunction with a myoprotector
WO2002032374A2 (en) *	2000-10-18	2002-04-25	Immunex Corporation	Methods for treating il-18 mediated disorders
EP1351678A2 (en) *	2001-01-02	2003-10-15	Elizabeth Shanahan-Prendergast	Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
EP1435991B1 (en)	2001-10-19	2008-10-15	Pharma Mar, S.A.	Use of aplidine for the treatment of pancreatic cancer
KR20060002778A (ko)	2003-03-12	2006-01-09	파르마 마르, 에스.에이.	개선된 항종양 치료

2004
- 2004-03-12 JP JP2006505957A patent/JP4584245B2/ja not_active Expired - Lifetime
- 2004-03-12 ES ES04720081T patent/ES2312979T3/es not_active Expired - Lifetime
- 2004-03-12 AU AU2004218883A patent/AU2004218883B2/en not_active Expired
- 2004-03-12 DK DK04720081T patent/DK1603584T3/da active
- 2004-03-12 MX MXPA05009742A patent/MXPA05009742A/es active IP Right Grant
- 2004-03-12 US US10/548,710 patent/US7381703B2/en not_active Expired - Lifetime
- 2004-03-12 PL PL04720081T patent/PL1603584T3/pl unknown
- 2004-03-12 RU RU2005131578/15A patent/RU2335294C2/ru active
- 2004-03-12 KR KR1020057016966A patent/KR101160320B1/ko not_active Expired - Lifetime
- 2004-03-12 SI SI200430878T patent/SI1603584T1/sl unknown
- 2004-03-12 EP EP04720081A patent/EP1603584B1/en not_active Expired - Lifetime
- 2004-03-12 PT PT04720081T patent/PT1603584E/pt unknown
- 2004-03-12 DE DE602004016126T patent/DE602004016126D1/de not_active Expired - Lifetime
- 2004-03-12 AT AT04720081T patent/ATE406171T1/de active
- 2004-03-12 NZ NZ541611A patent/NZ541611A/en not_active IP Right Cessation
- 2004-03-12 CA CA2519789A patent/CA2519789C/en not_active Expired - Lifetime
- 2004-03-12 WO PCT/GB2004/001062 patent/WO2004080477A1/en not_active Ceased
2005
- 2005-08-07 IL IL170136A patent/IL170136A/en active IP Right Grant
- 2005-10-11 NO NO20054668A patent/NO334264B1/no unknown
2008
- 2008-11-26 CY CY20081101367T patent/CY1108599T1/el unknown

Also Published As

Publication number	Publication date
KR20060006779A (ko)	2006-01-19
AU2004218883A1 (en)	2004-09-23
SI1603584T1 (sl)	2009-02-28
JP4584245B2 (ja)	2010-11-17
RU2335294C2 (ru)	2008-10-10
ES2312979T3 (es)	2009-03-01
EP1603584A1 (en)	2005-12-14
CA2519789A1 (en)	2004-09-23
WO2004080477A8 (en)	2004-11-11
IL170136A (en)	2014-04-30
JP2006519828A (ja)	2006-08-31
ATE406171T1 (de)	2008-09-15
US20060172926A1 (en)	2006-08-03
DK1603584T3 (da)	2009-01-05
WO2004080477A1 (en)	2004-09-23
CA2519789C (en)	2012-07-03
PT1603584E (pt)	2008-11-21
NZ541611A (en)	2008-04-30
KR101160320B1 (ko)	2012-06-26
US7381703B2 (en)	2008-06-03
NO334264B1 (no)	2014-01-20
CY1108599T1 (el)	2014-04-09
RU2005131578A (ru)	2006-01-27
AU2004218883B2 (en)	2009-10-01
US20070149445A9 (en)	2007-06-28
NO20054668L (no)	2005-10-11
DE602004016126D1 (de)	2008-10-09
MXPA05009742A (es)	2006-05-25
EP1603584B1 (en)	2008-08-27

Publication	Publication Date	Title
CY1108599T1 (el)	2014-04-09	Η απλιδινη στην αντιμετωπιση του πολλαπλου μυελωματος
SG149063A1 (en)	2009-01-29	Use of modified cyclosporins for the treatment of hcv disorders
TW200637522A (en)	2006-11-01	Skin treatment articles and methods
BR0309665A (pt)	2005-08-16	Tratamento de deficiência de alfa-galactosidase a
GB0201850D0 (en)	2002-03-13	Therapeutic treatment
ZA200407813B (en)	2005-10-18	Medicament for preventing and/or treating chronic rejection.
GB0216321D0 (en)	2002-08-21	Therapeutic treatment
MXPA05004697A (es)	2005-10-18	Soluciones farmaceuticas que comprenden un compuesto modafinil y uso para la fabricacion de un medicamento para tratar diferentes enfermedades.
GB0201674D0 (en)	2002-03-13	Medical treatment
GB0218879D0 (en)	2002-09-25	Medical treatment
MY141007A (en)	2010-02-12	Use of an alpha-2-delta ligand for the treatment of luts
MXPA04004306A (es)	2004-08-11	Uso de antagonistas del receptor de endotelina para el tratamiento de enfermedades tumorales.
HRP20080569T3 (en)	2008-12-31	Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin
WO2004080421A3 (en)	2005-06-09	Improved antitumoral treatments
MXPA05011830A (es)	2006-01-26	Peptidos para uso en el tratamiento de la obesidad.
UA88655C2 (ru)	2009-11-10	S-миртазапин для лечения прилива крови
IL175579A0 (en)	2006-09-05	Epithelium treatment methods and devices for treating the epithelium
NO20054034L (no)	2005-10-05	Fremgangsmate for behandling av hypotyroidisme.
GB0210464D0 (en)	2002-06-12	Therapeutic treatment
IL174134A0 (en)	2006-08-01	Use of a protein in the preparation of a medicament for treatment of fibrotic diseases
GB0327493D0 (en)	2003-12-31	Treatment medicament
AU2003255429A1 (en)	2004-03-03	Use of treosulfan and derivatives thereof for treating multiple sclerosis
MX2007004040A (es)	2007-05-24	Uso para alfa-simpatomimeticos con estructura de 2-imidazolina.
AU2003265321A8 (en)	2003-11-17	Treatments and methods for the treatment, diagnosis and prophylaxis
ATE413870T1 (de)	2008-11-15	Therapeutisches mittel zur behandlung von plasmazellneoplasien